SUTRO BIOPHARMA, INC. (STRO) Debt / Equity
- 2023-12-31: Debt/Equity Ratio 0.03.
- 2022-12-31: Debt/Equity Ratio 0.07.
- 2021-12-31: Debt/Equity Ratio 0.1.
Complete source-backed debt/equity ratio history.
- Available history
- 2021-12-31 to 2023-12-31
- Data captured
Historical Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2023-12-31 | 0.03 |
| 2022-12-31 | 0.07 |
| 2021-12-31 | 0.1 |
Annual Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2023-12-31 | 0.03 |
| 2022-12-31 | 0.07 |
| 2021-12-31 | 0.1 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |